The PreciSION CF trial results showed SION-719, when used alongside standard care, produced a placebo-adjusted sweat chloride change of only -1.0 mmol/L with a p-value of 0.7. Consequently, Sionna Therapeutics confirmed it will abandon the candidate as an add-on therapy. This failure strikes at the core of the firm’s pipeline, which relies heavily on its NBD1 stabilizer programs. In its 2025 Form 10-K, the company explicitly noted its substantial dependence on the success of these specific stabilizers.
Sionna Therapeutics Investors Face Losses After Trial Failure
A 92% collapse in Sionna Therapeutics share price followed the company’s announcement that its SION-719 cystic fibrosis drug failed to meet primary endpoints in a Phase 2a trial. The precipitous drop has triggered an investigation by Levi & Korsinsky into whether the company provided adequate disclosures to its shareholders.
Despite the market rout, Sionna reported a relatively stable balance sheet as of June 30, 2026, holding approximately $268.3 million in cash and marketable securities against a second-quarter net loss of $29.9 million. Legal counsel is now examining whether the company’s public communications sufficiently warned investors of the risks tied to the SION-719 program and the firm’s broader reliance on NBD1 technology. Investors who suffered financial losses are being prompted to review their brokerage records and evaluate potential recovery options.
Comments (0)
No comments yet. Be the first!